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NK cells are defective in acute myeloid leukemia (AML) at diagnosis. Here, we studied the 
kinetic of expression of the major activating and inhibitory receptors of NK, CD8 T, and γδ 
T cells in patients undergoing chemotherapy (CT) for the treatment of AML (n = 29). We 
showed that NK cells are the main affected population at diagnosis and that expression 
of activating receptors is partially restored within a few weeks after CT. CD8 T cells and 
γδ T cells are only weakly affected at diagnosis. Killer cell immunoglobulin-like receptor 
expression by NK cells, but not NKG2A and CD85j, was downregulated. Interestingly, 
the development of NK cells appeared altered as the most immature CD56bright NK cells 
were seriously underrepresented. Finally, we showed that NK cell functions were only 
partially restored 6 weeks after CT as degranulation capabilities of NK cells recovered, 
whereas cytokine production remained low. Our data point out NK cells as antitumor 
effectors peculiarly hampered by leukemic cells. This study may indicate a timeline when 
NK-mediated therapies or other immunotherapies could be performed, particularly for 
patients excluded of hematopoietic stem cell transplantation.
Keywords: nK cells, acute myeloid leukemia, chemotherapy, activating receptors, nK functions
inTrODUcTiOn
Immunity against cancer and in particular hematological malignancies relies on the capacity of 
effector immune cells to recognize and kill tumor cells and to alert other immune cells. The armed 
branch of the immune system responsible for tumor clearance encompasses NK cells, CD8+ αβ 
T cells (later referred to as CD8 T cells) and γδ T cells.
Abbreviations: NK, natural killer; AML, acute myeloid leukemia; CR, complete remission; CT, chemotherapy; HDs, healthy 
donors; KIRs, killer cell immunoglobulin-like receptors.
Table 1 | characteristics of patients.
characteristic N
Number of patients 29
age, years
Mean (SD) 70.17 (1.45)
Median [min–max] 70.00 [38.00–81.00]
≤65 4 (13.79)
>65 25 (86.21)
sex, n (%)
Male 19 (65.52)
Female 10 (34.48)
Fab category, n (%)
M1 4 (13.79)
M2 8 (27.59)
M4 9 (31.03)
M5 4 (13.79)
M6 2 (6.90)
Unclassified 2 (6.90)
cytogenetics, n (%)
Normal 21 (72.41)
Favorable 1 (3.45)
Complex 7 (24.14)
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Activation of CD8+ αβ T cells requires the peptidic antigen-
specific triggering of the TCR, in association with costimulatory 
molecules of the B7 family. γδ T cells recognize phospho-
antigens originating from the metabolism/mevalonate pathway 
of cells, which is often up-regulated in cancer cells. Activation 
of mature CD8 T cells and γδ T cells can be improved by sev-
eral activating coreceptors such as NKG2C, NKG2D, 2B4, and 
DNAM-1.
NK cells belong to the innate immune system and secrete 
many cytokines, such as GM-CSF, IL-10, or pro-inflammatory 
cytokines (IFN-γ and TNF-α), and chemokines. Activation 
of NK cells usually requires triggering of several cooperative 
receptors (1, 2). Some of them are specific for NK cells (natural 
cytotoxicity receptors, NKp30, NKp46, and NKp44), the oth-
ers can be shared with cytotoxic T cells (3). Of note, NKG2C 
is the activating counterpart of NKG2A, and both recognize 
HLA-E. Activation of NK cells is balanced by inhibitory recep-
tors, most of them recognizing classical HLA class I, or the 
non-classical class I HLA-E. Killer cell immunoglobulin-like 
receptors (KIRs) (CD158) are specific for class I HLA-A, B, and 
C, whereas NKG2A, a C-type lectin, recognizes HLA-E, and 
CD85j (LILRB1/ILT2) has a broad reactivity of HLA-I. Early 
immature NK cells express high levels of CD56 (CD56bright 
NK cells), high levels of NKG2A, and do not express CD16. 
After an intermediate stage characterized by a dim expression 
of CD16, NK cells lose partially CD56 expression and start to 
express inhibitory or activating KIRs, while gradually losing 
NKG2A expression (CD56dim NK cells) (4). These cells express 
high levels of CD16. Further maturation involves the acquisi-
tion of more KIRs, loss of NKG2A, and finally acquisition of 
CD57 (5, 6).
Reduced NK cell functions have been shown to promote 
cancer (7). NK cell importance in leukemia control has been 
evidenced by the pioneering study of Ruggeri and was followed 
since by many centers (8, 9). Hence, NK cells are found pro-
foundly altered in solid cancers, such as breast cancer, neuro-
blastoma, and GIST, and in hematological malignancies such as 
multiple myeloma or acute myeloid leukemia (AML) (10–13). 
These phenotypic and functional alterations strongly suggest 
the need for tumor cells to hamper NK cell-mediated recogni-
tion (14). Although the mechanisms behind the interaction and 
destruction of leukemic cells are not yet clearly defined, the high 
rate of relapse in AML suggests these mechanisms are altered 
and profit to leukemic cells that can escape from the immune 
system (15, 16).
The current mainstay of AML treatment is based on conven-
tional chemotherapy (CT) using anthracyclines and cytarabine, 
and hematopoietic stem cell transplantation (HSCT) for patients 
with poor prognosis features. With this treatment, about 50–80% 
of patients attain complete remission (CR). However, the 2-year 
survival is only 15–50% due to frequent relapses (17). Although 
a lot of them have poor-risk disease, HSCT is often not feasible 
because of comorbidities. There is thus an urgent need to develop 
new immunotherapeutic approaches that represent alternatives 
to HSCT such as vaccines, monoclonal antibodies, or immu-
nomodulatory drugs (IMIDs). However, these approaches often 
require a functional immune system to facilitate the clearance 
of tumor cells. Therefore, it is relevant to monitor the status of 
immune cells, since so far, little is known about the effects of CT 
drugs on immune cells, with very few in vitro studies performed 
on cytotoxic T cells or NK cells (18, 19).
In this study, we analyzed the phenotype of peripheral 
blood NK cells, γδ T cells, and CD8 αβ T cells (CD8 T cells) 
of elderly patients treated with CT for AML. Blood samples 
were collected at diagnosis, remission, and various time points 
following consolidation CT in order to evaluate potential altera-
tions following CT. Our data revealed important phenotypic 
alterations of NK  cells, contrasting with limited phenotype 
alteration of γδ T cells and CD8 T cells. The most immature 
NK cell population was absent at diagnosis and recovered slowly 
after CT. NK cells presented low cytolytic activity at diagnosis 
that recovered with time, but their capacity to produce pro-
inflammatory cytokines was durably impaired. Overall, these 
data provide the basic knowledge required for the design of 
clinical trials of immunotherapies for the treatment of AML 
in the elderly.
PaTienTs anD MeThODs
Patients
We enrolled 29 elderly patients (60–80  years old) with non-
promyelocytic AML according to WHO criteria in first CR fol-
lowing induction CT (3 + 7 regimen). All patients have received 
an induction and one consolidation CT before inclusion. All 
patients received informed consent. The study was approved by 
a local ethics committee and the national institution [AFSSAPS 
(Agence Française de Sécurité Sanitaire des Produits de Santé), 
No DGS 2006/0396]. Patient peripheral NK, γδ T, and CD8 
T cells were analyzed at diagnosis, the day before the second 
consolidation CT (W0), and every other week after treatment 
for 8  weeks (Figure S1 in Supplementary Material). Patient 
characteristics are presented in Table 1. All patients were in CR 
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at W0. Induction CT was as follows: daunorubicin 45  mg/m2 
D1–D3, cytarabine 100 mg/m2 D1–D7; consolidation CT 1 is as 
follows: daunorubicin 45 mg/m2 D1–D2, cytarabine 50 mg/m2 
subcutaneous twice daily D1–D5; consolidation CT 2 is as fol-
lows: idarubicin 8 mg/m2 D1, cytarabine 50 mg/m2 subcutaneous 
BID D1–D5.
Fifteen healthy donors (HD), age-matched, were used as 
controls and were obtained from the Etablissement Français du 
Sang. Median age of HD was 72.2 years [65.6–76.4] and the ratio 
F/M was 8/7. No major past clinical history was noticed for these 
donors.
Phenotypic studies
Peripheral blood samples from HD and AML patients were pro-
cessed and cryopreserved until use. After thawing, PBMCs were 
processed for flow cytometry experiments. The antibodies used 
for these experiments are listed in Table S1 in Supplementary 
Material. 7-AAD was used as a live/dead discrimination marker. 
Protocols and FACS analysis were performed according to pub-
lished protocols (1).
Proliferation assays
PBMCs were thawed up, washed twice in PBS, and incubated 
20  min with 2.5  µM CellTrace Violet at 37°C. Cells were then 
washed twice in PBS before resuspension in RPMI containing 
10% FCS, 100 UI/mL IL-2, and 10 ng/mL IL-15. After 6 days of 
culture, cells were harvested and prepared for flow cytometry 
analysis. The antibodies used for these experiments are listed in 
Table S1 in Supplementary Material.
Degranulation and cytokine Production 
assays
PBMCs were thawed up and incubated overnight at 37°C with 
RPMI 10% FCS (complete medium) alone or with complete 
medium containing IL-2 (100 UI/mL) + IL-15 (10 ng/mL) or IL-12 
(5 ng/ml) +  IL-18 (10 ng/mL). Cells were then incubated with 
K562 cells (ratio 1:10) at 37°C for 4 h in the presence of GolgiPlug 
(Life Technologies). The antibodies used for these experiments 
are listed in Table S1 in Supplementary Material. Functional tests 
with NK cells at diagnosis could not be performed because of lack 
of material and because of the extremely low frequency of NK 
cells counts at this time point.
cytotoxicity assays
NK cells were isolated using magnetic isolation kit (StemCell 
Technologies). The purity of NK cells was determined by flow 
cytometry and was >98%. K562 target cells were labeled with 51Cr 
(Perkin-Elmer). After three washes, NK cell cytotoxicity against 
the HLA class I-deficient K562 cell line was evaluated with a 
standard 4-h 51Cr-release assay at various effector/target ratios 
(10:1 and 2:1). All experiments were performed in triplicate.
nK cell Functions
Effector functions of NK cells were assessed by flow cytometry. 
For target cell stimulation, 1 × 106 PBMCs were mixed with K562 
(ratio 10:1) for 4 h at 37°C and 5% CO2 as previously described 
(20). Unless otherwise specified, PBMCs were kept unstimulated 
before functional assays. When indicated, PBMCs were primed 
overnight with recombinant (r)IL-2 (50 UI/mL) and rIL-15 (5 ng/
mL) prior to functional assays (Figure S2A in Supplementary 
Material). For cytokine production assays after cytokine stimula-
tion, PBMCs were thawed, counted, and incubated for 18 h in 
the presence or absence of rIL-12 (5 ng/mL) and rIL-18 (20 ng/
mL). Cells were then incubated with or without target cells with 
Golgiplug (BD Biosciences) for four additional hours, and then 
prepared for FACS analysis.
statistical analysis
Statistical analyses were performed using GraphPad Prism 
software. For comparison between multiple matched samples, a 
Friedman test with a Dunn’s posttest was performed. For com-
parison between two independent groups, a Mann–Whitney test 
was performed. Statistical significance was indicated as *P < 0.05, 
**P  <  0.01, and ***P  <  0.001. In all graphs, data represent 
mean ± SEM.
resUlTs
reconstitution of antitumor effectors  
after cT
We analyzed the peripheral blood of 29 patients diagnosed for 
a primary AML at diagnosis, after induction CT, and during 
second consolidation therapy cycle (Figure S1 in Supplementary 
Material and Section “Materials and Methods”). NK, γδ and 
CD8+ T cell absolute counts were calculated and compared to 
those of age-matched HDs. At diagnosis, lymphocyte counts were 
higher than that of HDs and were restored after CR (Figure 1A). 
As expected, 2 weeks after the second cycle of consolidation CT, 
lymphocyte counts significantly dropped but recovered by W6. 
CD8+ T cell numbers were higher at diagnosis, whereas NK and 
γδ cell numbers were comparable to control (Figure 1B). γδ T 
cell counts were back to normal after CR and remained constant. 
CD8 T cell counts dropped after induction and reached the levels 
of HD after the second consolidation, but rised again to stay high 
compared to HD (not significant). Similar to the other popula-
tions, NK cell counts dropped during induction and the first 
consolidation, eventually increased but cell counts never reached 
the levels of HD.
expression of activating receptors in 
cytotoxic effectors during cT
We next analyzed whether expression of coactivating receptors 
was affected during the course of AML treatment (Figure 2A). 
NKG2C expression was found higher on NK cells from patients 
at diagnosis compared to HDs (P  =  0.0029) and expression 
remained high during the treatment. DNAM-1 and 2B4 were 
found downregulated at diagnosis (P = 0.0024 and P < 0.0001, 
respectively). Interestingly 2B4 expression remained lower com-
pared to HD during the study, whereas DNAM-1 expression was 
completely restored. NKG2D expression was unaffected during 
the study albeit the comparison with AML at diagnosis could not 
be tested. Finally, we confirmed in this study the downregulation 
FigUre 1 | Kinetics of cytotoxic lymphocyte reconstitution. Kinetics of NK cells (round dots), CD8+ T cells (squares) and γδ T cells (triangles) reconstitution at 
the indicated time points. Cell counts (mean ± SEM) were measured at diagnosis of the disease, before the second consolidation (week 0, W0), at week 2, 4, 6, and 
8 (W2, W4, W6, W8). (a) Absolute lymphocyte count. Dotted line corresponds to the mean of lymphocyte counts from 15 healthy donors (HD). (b) NK, γδ T, and 
CD8+ αβ T cell absolute counts. Horizontal lines correspond to the mean of NK, γδ T, and CD8+ αβ T cell counts from HD. When indicated a Kruskal–Wallis 
non-parametric test with Dunn’s posttest was performed to compute the P value for the comparisons (*P < 0.05, **P < 0.01, ****P < 0.0001).
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of NKp30 and NKp46 at the diagnosis (P < 0.0001 and P = 0.0024, 
respectively). NKp30 expression was partially restored at W8 
(MFI  =  953  ±  134 vs HD: MFI  =  1,304  ±  108, P  =  0.0365), 
whereas that of NKp46 was completely restored, even higher than 
controls (W6: MFI = 3,340 ± 306 vs HD: MFI = 1,921 ± 212, 
P = 0.0017 and W8: MFI = 3,221 ± 465 vs HD: MFI = 1,921 ± 212, 
P  =  0.0188). Noteworthy, neither CD56 nor CD16 expression 
was altered in patients at diagnosis or during treatment (data 
not shown). With respect to γδ T cells and CD8 T cells, NKG2C, 
NKG2D, DNAM-1, and 2B4 expression was also analyzed and 
revealed a completely different picture. 2B4 expression was 
downregulated at diagnosis (γδ T cells: MFI: 1,892 ± 237 vs HD: 
MFI = 2,300 ± 119, P = 0.0013; CD8 T cells: MFI: 1,640 ± 146 
vs HD: MFI = 1,827 ± 123, P = 0.05) and restored at the end of 
the study. NKG2C, NKG2D, and DNAM-1 were expressed with 
similar frequencies and MFI compared to controls.
Overall, with respect to activating receptors, NK cells seemed 
to be the main effector population affected during the treatment 
of AML patients. We next decided to focus the study on NK cells.
expression of hla receptors in nK cells 
during cT
We next analyzed the expression (frequency) of HLA receptors, 
i.e., NKG2A, CD85j, and KIR/CD158, on NK cells from patients 
under treatment (Figure 2B). The anti-CD158 antibodies used 
here do not discriminate between inhibitory and activating 
KIRs. Our analyses revealed a downregulation of CD158a/h and 
CD158b1/b2/j at diagnosis and after reaching CR (W0) compared 
to HD. NKG2A expression was not drastically affected during 
time compared to controls at all time points, although there was 
some increase at W6 and W8 compared to CR. In contrast, CD85j 
was more frequent on NK cells from patients at diagnosis and 
before the second cycle of consolidation CT. Expression tended to 
decrease over time during treatment, although remaining slightly 
higher than HD. Of note, frequencies of HLA receptors in γδ T 
cells and CD8 T cells were slightly altered during the study, with 
a non-significant increase of CD158b1/b2/j and CD85j (Figure S2 
in Supplementary Material).
Kinetics of early stages of nK cell 
Maturation during cT
We next sought to analyze whether NK cell early maturation 
was normal in patients before and after AML treatment. 
Combinations of CD56, CD16, and NKG2A define different 
steps of NK cell maturation (4, 5). CD56 expression as well as 
frequencies of CD16 and NKG2A positive cells out of total NK 
cells were comparable to HD (data not shown and Figure 2B). 
However, it is known that NKG2A is expressed by all CD56bright 
NK cells and CD16 expression defines two subsets (4). 
CD56bright NK cells are usually a rare population compared to 
CD56dim NK cells, and therefore, information about these cells 
may be masked when looking at the total NK level. Therefore, 
we analyzed the combinations of these three markers in order 
to identify the different maturation subsets based on CD56, 
CD16, and NKG2A markers. We observed a profound loss 
of total CD56bright and CD56bright CD16− NK cells at diagnosis 
[Figures  3A,B (left and right panels, respectively); Figure S3 
in Supplementary Material]. After induction and reaching CR, 
total CD56bright were present at low frequency and continued to 
rise during consolidation (Figure 3C).
Functional Properties of nK cells after cT
NK cells from AML patients have defective cytolytic activities 
(11, 14, 21). We next sought to verify whether cytotoxicity was 
restored during treatment and whether other functions of NK cells 
were affected during treatment by CT. Degranulation (CD107a) 
and IFN-γ or TNF-α production assays were performed after 
interaction with K562 cells. Degranulation capacities of total 
NK cells during recovery could not be compared to NK cells at 
diagnosis, due to the paucity of NK cells, and was thus compared 
to HD or total NK cells at CR. Degranulation was impaired in NK 
cells from patients in CR (W0) but was, at least partially, restored 
FigUre 2 | Kinetics of activating and inhibitory receptor expression. (a). Global view of expression of activating receptors was measured by flow cytometry 
on NK, γδ T, and CD8+ αβ T cells at the indicated time points. MFI (unimodal expression) and percentage of positive cells (bimodal expression) were normalized and 
hierarchically clusterized with Tmev software. Comparison with healthy donors (HDs) was performed, and data are represented with colors reflecting higher (red) or 
lower (green) expression compared to HDs. Gray squares correspond to non-determined values. (b). Expression of CD158a/h, CD158b1/b2/j, NKG2A, and CD85j 
by NK cells from HD and patients at the indicated time points. Bars represent the median expression and when indicated a Kruskal–Wallis non-parametric test with 
Dunn’s posttest was performed to compute the P value for the comparisons (*P < 0.05, **P < 0.01, ***P < 0.001).
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during consolidation (Figure  4A, black bars). Degranulation 
never reached the level of HD, and at W8, NK cells displayed 
a somewhat reduced degranulation capacity compared to W6 
(non-significant). Interestingly, despite reduced degranulation at 
early time points, we found that perforin content in NK cells (and 
T cells) was higher compared to HD (Figure S4 in Supplementary 
Material). Similar to degranulation, IFN-γ production was altered 
in patients in CR, but we did not observe any restoration of the 
FigUre 3 | continued
6
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FigUre 3 | Kinetics of immature nK cells reconstitution. (a) Example of reconstitution of CD56bright NK cells in a patient following treatment. The figure 
displays the reapparition of CD56bright NK cells expressing or not CD16 (top) or NKG2A (bottom). (b) Frequencies of total CD56bright NK cells (left panel) or CD56bright 
NK cells lacking CD16 expression (right panel). (c) Summary figure of reconstitution of the immature CD56bright NK cell subset after induction and consolidation 
therapies. Data represent Tukey whisker boxes, with outliers represented as round dots. When indicated a Kruskal–Wallis non-parametric test with Dunn’s posttest 
was performed to compute the P value for the comparisons (*P < 0.05, **P < 0.01, ***P < 0.001).
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capacity of NK cells to produce IFN-γ (Figure  4A, gray bars) 
and TNF-α (not shown) after interaction with K562 compared 
to HD. In order to verify whether the whole cytokine production 
machinery was impaired, and not only the capacity to respond 
to target cells, we incubated overnight NK cells with a cocktail 
of IL-2/IL-15 or IL-12/IL-18 and then incubated these NK cells 
with K562 cells (Figure 4B). As CD56bright NK cells and CD56dim 
NK cells were identifiable at W0 (in contrast to diagnosis), these 
two subsets were gated and analyzed. After interaction with target 
cells, both CD56dim and CD56bright NK cells from patients at W0 
pretreated with IL-2/IL-15 or IL-12/IL-18 displayed a significant 
increase in degranulation as well as IFN-γ and TNF-α production, 
similar to controls. Interestingly, functions of cytokine-primed 
CD56dim NK cells at W4 (4 weeks after the second consolidation 
cycle) were somewhat decreased compared to functions meas-
ured at W0. Regarding CD56bright NK cells, a slight decrease of 
CD107a and IFN-γ was observed, but generally, the effect was 
minor compared to CD56dim NK cells.
Finally, we analyzed the capacity of NK cells to proliferate in 
response to IL-2 and IL-15 stimulation (Figure 5). By means of 
CellTrace Violet dilution assay, we observed that NK cells from 
patients at W0 and W4 had a high capacity of proliferation, 
similar to controls. As expected, CD56bright NK cells proliferated 
more than CD56dim NK cells as revealed by the high frequency of 
cells with longer history of cell division (>2 generations). Of note, 
NK cells from patients at diagnosis were not analyzed because of 
the lack of CD56bright NK cells. Altogether these data revealed that 
NK cell effector functions that can be triggered by target cells are 
altered at early steps of AML treatment and that only degranula-
tion is restored over time. By contrast, the sensitivity to exogenous 
cytokine stimulation was not affected by consolidation CT.
DiscUssiOn
The treatment of hematological malignancies, including AML, 
requires the standardized and recommended use of anthracyclines 
and aracytine (17). Frequent relapse is the proof that the initial 
treatment is not sufficient and leaves the patient with a minimal 
residual disease that eventually overcomes immune surveillance, 
leading to relapse. Little is known about the status of the immune 
system during the early steps of CT in AML, in particular with 
NK cells. Here, we studied effector lymphocytes (NK, CD8, γδ T 
cells) frequencies during the early course of treatment of elderly 
AML patients. We analyzed the expression of the main activating 
and inhibitory receptors in these cells. Focusing on NK cells, 
we have analyzed their effector functions in response to target 
cell or cytokine stimulation. Our data revealed that NK cells are 
the main population affected at diagnosis or during treatment. 
Although NK cells expand after the induction CT, they remain 
probably more sensitive to the consolidation CT because the NK 
cell counts remained lower than that of HD, as described before 
(22). In contrast, CD8 T cells and γδ T cells were more frequent 
FigUre 4 | effector functions of nK cells following chemotherapy. (a) Specific lysis of target cells (black bars, left axis) and intracellular production of IFN-γ 
(gray bars, right axis) after interaction between NK from healthy donors (HDs) or patients at the indicated time points and K562 cells. Histogram represents mean 
and bars represent SEM. (b) Effect of cytokine priming on degranulation and production of IFN-γ and TNF-α upon interaction with K562 cells. NK cells from HDs 
(n = 3) and patients (n = 5) at the indicated time points were treated overnight with medium only (white bars), IL-2 + IL-15 (black bars) or IL-12 + IL-18 (gray bars). 
Cells were then washed and incubated for 4 h with K562 cells. Effector responses were analyzed as indicated in the Section “Materials and Methods.” The figure 
depicts CD56dim (left) and CD56bright (right) identified with the flow cytometry analysis software.
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FigUre 5 | Proliferation capacities of nK cells before and during consolidation. Proliferation capacities of NK cells during chemotherapy (CT). NK cells from 
healthy donors or patients before (W0) and after the first cycle of consolidation CT were isolated from peripheral blood, stained with CellTrace Violet, and cultured for 
6 days in IL-2-containing medium. The figure displays CellTrace Violet dilution reflecting cell proliferation for CD56dim NK cells (top) and CD56bright NK cells (bottom). 
The histograms indicate the frequency of non-proliferating cells (generation 0) and proliferating cells (generations 1–6). Data represent mean ± SEM. Insets show a 
representative donor or patient (n = 3 and n = 5, respectively).
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than in HDs during the entire study. In addition, NKG2C, 
DNAM-1, 2B4, and NKG2D were expressed on all T cells at 
similar levels compared to HD. In contrast, confirming previous 
studies, DNAM-1, 2B4, NKp30, and NKp46 were downmodu-
lated at diagnosis on NK cells. The impact of treatment resulted in 
a partial or total restoration of NKp30 and NKp46, respectively, as 
previously shown (14), and a restoration of DNAM-1 expression. 
Surprisingly, 2B4 expression remained low during the 8 weeks of 
observation. The fact that the alterations mostly concerned NK 
cells likely reflects their involvement in the control of leukemia 
progression. Alternatively, the general downmodulation of 
NK-activating receptors shed light on the suppressive pathway 
that leukemia use to hamper innate immune recognition. Several 
mechanisms have been suggested explaining how cancer cells 
impair NK cell functions, such as TGFβ-1 production by tumor 
cells (10), or the production of histamine and reactive oxygen spe-
cies by phagocytes (23). A phase III clinical trial using histamine 
dihydrochloride in addition to IL-2 improved the leukemia-free 
survival of AML patients (24). Alternatively, it was suggested that 
AML-induced alteration of NK cells was mediated by IL-10 (21). 
Our study, along with previous studies, suggests that chemoresist-
ant remaining tumor cells may remain untargeted by defective 
NK cells. Hence, the weak expression of activating NK receptors 
is expected to result in a lack of recognition of residual tumor 
cells. An interesting parameter to analyze would be to compare 
the level of NK cell receptor expression with the incidence of 
relapse. In line, a recent studies identified correlations between 
NK cell receptor profiles with OS and relapse risk (25).
In accordance with defective receptor expression at diagnosis, 
degranulation, and IFN-γ production upon interaction with 
target cells were defective at diagnosis. Beside intrinsic insuf-
ficiency to degranulate against classical HLA-negative NK target 
cells, AML-NK cells, and also AML-T cells, display a reduced 
capacity to form solid conjugates and effective immune synapse 
with leukemic cells (26, 27). Albeit degranulation properties 
were restored over time, cytokine production remained impaired 
along the time course of the study. These data suggest that NK cell 
recovery after CT is incomplete. Interestingly, at W4 functions 
of NK cells after exogenous cytokine and target cell stimulation 
was further decreased compared to W0. Although this finding 
should be confirmed, it suggests that at this time unknown 
factors may delay the reconstitution of NK cell function. These 
data are similar to the reconstitution of NK functions after stem 
cell transplantation (SCT) where degranulation is functional but 
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not pro-inflammatory cytokine production (1, 28). It seems that 
degranulation capacities of NK cells during immune reconstitu-
tion are a faster process compared to regulatory functions. These 
data warrant more investigation such as longer time points of 
observation since in SCT it takes up to 1 year to fully recover 
IFN-γ or TNF-α production capabilities (1). Furthermore, it 
would be interesting to determine whether, like for SCT, a fast 
cytokine production recovery correlates with a lower probability 
of relapse.
In addition to activating NK receptors, we also analyzed the 
expression of HLA receptors. Expression of classical HLA-I 
receptors (i.e., KIRs) was downmodulated in NK cells at the 
diagnosis and CR, but was restored over time, suggesting a 
potential break of tolerance, which is unfortunately hampered 
by the downregulation of activating receptors. NKG2A was not 
affected at diagnosis nor during treatment. Thus, NK cell activa-
tion remains tightly controlled, likely by tumor cells, keeping NK 
cells tolerant to remaining tumor cells.
Despite the normal expression of CD16 and NKG2A, we 
could not exclude alterations in the development of NK cells 
both at diagnosis and during the treatment, since CT induces 
aplasia. For instance, after HSCT, the population of immature 
NK cells is prominent during several months after graft (1, 29). 
Surprisingly, when we measured the ratio between CD56bright 
NK cells (immature) and CD56dim NK cells, we observed a dra-
matic reduction in the frequencies of CD56bright NK cells, and 
particularly in the most immature CD56bright CD16− NK cells. 
The fact that these cells, as well as CD56bright CD16+ NK cells, 
recover over time suggest that leukemic cells have somehow a 
deleterious effect on this population. In our cohort, we observed 
an increase of CD56bright NK cell frequency between the diagno-
sis and W0 just before the second induction and a continued 
increase until the end of study. This observation suggests that 
consolidation CT has little impact on NK cell reconstitution. We 
cannot exclude that abnormal NK cell differentiation is main-
tained at these early time point from induction as the cohort 
is too small. Our observation seems to contradict the study by 
Dauguet et al. showing that most patients at first CR displayed 
an unusual high frequency of CD56bright NK cells (30). However, 
we did not analyze our patients during this very early phase of 
treatment (15–30 days post induction CT), and we could have 
missed a critical period of time where NK cells undergo rapid 
expansion and differentiation as a sign of homeostatic prolifera-
tion. This subversion of NK cell maturation by tumor cells has 
been observed in other cancer settings such as breast cancer 
(31). Interestingly, a study by Harlin et  al. suggested that the 
microenvironment may alter NK cell biology and notably sur-
vival by producing reactive oxygen species, which kill CD56dim 
NK cells but somehow spare CD56bright NK cells (32). It would 
be interesting to test whether metabolism, particularly oxygen 
metabolism, is altered during these early phases of AML treat-
ment. Obviously other mechanisms may be involved. In line, 
studies in mouse models have also evidenced a direct impact of 
tumor cells, including AML-like cancer, on NK cell maturation 
(33, 34). Importantly, the recent study by Mundy-Bosse et  al. 
also showed that CD56bright NK cells are less frequent in AML 
patients at diagnosis (34). Thus, our study confirms the study of 
Mundy-Bosse et al. Interestingly, the microRNA mir-29b seems 
to be involved in the process of maturation blockade both in 
mice and humans (34). EOMES and T-BET are targets of Mir-
29b, and these transcription factors are critical for early NK cell 
differentiation. Nonetheless, studies are required to elucidate 
the link between leukemic cells and mir-29b or other potential 
targets of leukemic cells.
A more thorough analysis with additional differentiation 
markers, such as combination of KIRs, NKG2A, and CD57, 
should be performed in order to identify the extent of NK cell 
maturation recovery during consolidation therapy. Addressing 
the mechanisms of such a defect would be difficult in humans. 
A blockade of NK cell differentiation would likely result in a 
defective production of mature NK cells, which is not the case 
in our cohort and according to previous studies. Oppositely, 
an acceleration of maturation of NK cells, while preserving a 
normal production of NK cells, would potentially result in an 
accumulation of more mature NK cells. Accordingly, in a dif-
ferent cohort, we have observed an accumulation of late-stage 
matured CD56dim NK cells expressing the markers CD57 and 
KIRs in AML patients at diagnosis (35). Interestingly, these 
two populations (i.e., immature CD56bright and the most mature 
CD56dim KIR+ CD57+ NK cells) are distinguished by their 
differential capacities to respond to cytokines and to regulate 
other immune cells via cytokine production capacities (5, 36). 
The reduction of CD56bright NK cell pool could then participate 
to the immune tolerance to leukemic cells. Interestingly, this 
dichotomy between CD56bright and CD56dim ratio has been 
recently associated with additional defects in NK cells and cor-
relates with clinical outcome of patients and may have potential 
consequences on the results of future NK cell-based immu-
notherapies (25). It seems of importance to note that at W0, 
CD56bright NK cells that had reappeared behaved in a comparable 
way to HDs’ CD56bright NK cells. Hence, cytokine production, 
degranulation, and proliferation capacities were similar. These 
data suggest that these cells may have recovered fully, or simply 
that the blockade of maturation is paralleled but not linked to 
alterations of phenotype and functions.
Our data show that NK cells are present in almost normal 
numbers in patients with AML in CR and NK cells remain 
present after consolidation CT. Our data provide new insights 
in the optimal period to introduce NK cell-based immuno-
therapy, i.e., when NK cells have recovered sufficient effector 
functions such as cytokine production and cytotoxicity. 
Many NK cell-based immunotherapies have been developed 
over the last decades, with allogeneic or autologous NK cells 
(37). In 2005, haploidentical NK cells were administered in 
a non-transplantation setting and resulted in a substantial 
improvement of patient clinical outcome (38). More recently, 
in vivo targeting of NK cells with antibodies was investigated: 
IPH2101 is a first-in-class anti-KIR mAb that blocks inhibi-
tory KIR–ligand interactions, leading to restoration of NK cell 
functions (39). A phase II trial in AML elderly patients in first 
CR1 (NCT01687387) is in progress and several other trials are 
ongoing in different cancers alone or in combination with other 
treatments. The future introduction of a first-in-class anti-
NKG2A blocking antibody (IPH2201) will also provide a novel 
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FigUre s2 | expression of inhibitory receptors by αβ and γδ T cells. 
Expression of CD158a/h, CD158b1/b2/j, NKG2A, and CD85j by αβ and γδ 
T cells from healthy donors (HDs) and patients at the indicated time points. Bars 
represent the median expression of the indicated markers. Horizontal lines 
correspond to the mean expression of HDs (n = 15).
FigUre s3 | expression of inhibitory receptors by αβ and γδ T cells. 
Gating strategy of NK cells from patients at diagnosis and during treatment. One 
representative patient is shown at diagnosis and week 6.
FigUre s4 | expression of perforin by nK cells and αβ and γδ T cells. 
Expression of perforin was measured by intracellular staining and flow cytometry 
analysis on the indicated populations from peripheral blood of patients at the 
indicated time points. Histograms represent mean ± SEM. Horizontal lines 
correspond to the mean expression of perforin in cells from healthy donors 
(n = 15).
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